Our mission is to transform the industry through the development of the next breakthrough in cancer research through high quality Phase 1 clinical trials
202511/27
GSK5460025 (GlaxoSmithKline) Global First Subject First Dose
View More
202511/05
NEXT Oncology Expands to Japan in Joint Venture Partnership With Kansai Medical Univ...
202509/01
Expanding FIH Phase 1 Inpatient Wards for Reinforcing Early Phase Oncology Clinical ...
